NEWS

Mixed views on Broad’s fate after EPO revokes CRISPR patent
Life Sciences Intellectual Property Review
Daniel Lim, senior associate at Allen & Overy, attended the hearing at the EPO. He has since told LSIPR that while some of Broad’s other opposed CRISPR patents will be vulnerable to revocation based on lack of priority, the institute does have other …

and more »

Mechanisms of Resistance for CAR T Therapy
OncLive
And so, when we’ve had patients who relapsed and still retained the CD19 antigen and they’ve generally had a loss of CAR T cells, they, in general, do not respond to a second infusion. And in those who don’t respond, we’ve been able to show that they …

and more »

UK’s CGT Catapult Partners with Freeline to Build Gene Therapy Manufacturing Platform
Genetic Engineering & Biotechnology News
The Cell and Gene Therapy (CGT) Catapult said today it will partner with Freeline Therapeutics to build the gene therapy developer’s proprietary manufacturing platform at the CGT Catapult’s large-scale GMP manufacturing center in Stevenage …

Treating Advanced Bladder Cancer in the Future
OncLive
Daniel J. George, MD: Immunotherapy in bladder cancer is here to stay. There is no doubt about the fact that we have changed this platinum-refractory setting. There’s no doubt in my mind that this is going to become more and more a part of our …

and more »

The Challenge of Immunotherapy: Staying on Target
Genetic Engineering & Biotechnology News
Some of the side effects of immunotherapy resemble symptoms of autoimmune diseases; he added that experts treating Crohn’s disease might be able to help oncologists treat colitis in cancer patients, for instance. Immune checkpoint blockade works by …

MSI Testing’s Impact on Immunotherapy in Gastric Cancers
OncLive
And our data from MSKCC in the metastatic setting, which was recently published in Cancer Discovery, shows that MSI metastatic gastric cancer progresses on systemic chemotherapy within the first 4 months of treatment, showing that these tumors are …

and more »

Novartis sBLA for CAR–T Therapy Kymriah Accepted by FDA
Nasdaq
A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. CAR-T is manufactured for individual patients using their own cells thereby making it different from typical small molecule or biologic therapies …
Novartis gets US priority review for Kymriah for adults with lymphomaReuters
Novartis’ Kymriah nabs speedy reviews in US, Europe for lymphoma treatmentPharmaceutical Business Review
US FDA grants priority review status to Novartis’ sBLA for Kymriah to treat adults with r/r DLBCLpharmabiz.com

all 7 news articles »

CRISPR: the gene editing tool making the world go round
Lexology
The battle over clustered regularly interspaced short palindromic repeat (CRISPR) technology between Feng Zhang and the Broad Institute at the Massachusetts Institute of Technology on the one side and Jennifer Doudna, Emmanuelle Charpentier, Krzysztof …
Mixed views on Broad’s fate after EPO revokes CRISPR patentLife Sciences Intellectual Property Review

all 2 news articles »